Astellas gets EU approval for AML drug Xospata

The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival dr

Astellas maintains lead over Daiichi Sankyo with CHMP okay f...

Oncology round-up: AZ and Daiichi score key trial win with b...

AZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, an antibody-drug conjugate, in patients with an advanced

AbbVie raises hopes for blood cancer patients

AbbVie has filed its Venclexta (venetoclax) for a new use that it hopes could change the treatment of one of the most aggressive cancers – acute myeloid leukaemia (AML).

Pfizer will have to cut price of AML drug Mylotarg after NIC...

NICE blocks access to 65% of patients on cost grounds